HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$4.31
Day range
$4.39 - $4.64
Year range
$2.71 - $5.10
Market cap
885.52M USD
Avg Volume
2.74M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 1.05M | -33.23% |
Operating expense | 3.69M | -21.71% |
Net income | -3.76M | 70.03% |
Net profit margin | -357.37 | 55.11% |
Earnings per share | — | — |
EBITDA | -7.63M | 34.28% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 91.47M | -25.40% |
Total assets | 94.62M | -28.16% |
Total liabilities | 18.04M | -47.46% |
Total equity | 76.58M | — |
Shares outstanding | 195.48M | — |
Price to book | 10.77 | — |
Return on assets | -19.87% | — |
Return on capital | -23.48% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -3.76M | 70.03% |
Cash from operations | -4.68M | 54.63% |
Cash from investing | -1.36M | -110.15% |
Cash from financing | 1.64M | 15.41% |
Net change in cash | -4.40M | -198.13% |
Free cash flow | -1.95M | 77.37% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
19
